X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Cipla Fact Sheet, Cipla Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Cipla Fact Sheet   (CIPL)

Here is the latest financial fact sheet of Cipla. For more details, see the Cipla quarterly results and Cipla share price and chart. For a sector overview, read our pharmaceuticals sector report.

CIPLA Price History

Price Rs 640.2
Mkt Cap Rs m 514,815
Vol '000 247.2
P/E X 39.3
P/CF X 18.8
EPS (TTM) Rs 16.3
% ch % 0.0
No. of shares m 804.21
% ch week % 0.4
% ch 1-mth % -3.4
% ch 12-mth % 1.4
52 week H/L Rs 678.0/508.1
(As on Oct 17, 2018 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

CIPLA Financials

No. of Mths
Year Ending
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
12
Mar-18
*
5-Yr Chart
Click to enlarge
CIPLA EQUITY SHARE DATA
High Rs450753748622663 
Low Rs364369495458479 
Sales per share (Unadj.) Rs126.7141.3171.7181.9189.0 
Earnings per share (Unadj.) Rs17.314.717.212.917.6 
Diluted earnings per shareRs17.314.717.212.917.6 
Cash flow per share (Unadj.) Rs21.921.026.629.334.0 
Dividends per share (Unadj.) Rs2.002.002.002.003.00 
Adj. dividends per shareRs2.002.002.002.003.00 
Dividend yield (eoy) %0.50.40.30.40.5 
Book value per share (Unadj.) Rs125.2132.6143.3155.9176.7 
Adj. book value per shareRs125.0132.4143.2156.0176.9 
Shares outstanding (eoy) m802.92802.96803.38804.51805.12 
Bonus/Rights/Conversions  -ESOPESOPESOPESOP 
Price / Sales ratio x3.24.03.63.03.0 
Avg P/E ratio x23.538.136.142.032.5 
P/CF ratio (eoy) x18.626.723.418.416.8 
Price / Book Value ratio x3.34.24.33.53.2 
Dividend payout %11.613.611.615.517.1 
Avg Mkt Cap Rs m326,829450,139499,381434,516459,724 
No. of employees `000NANA24.123.023.6 
Total wages/salary Rs m15,43019,73724,34026,33826,901 
Avg. sales/employee Rs ThNMNM5,723.76,349.16,446.1 
Avg. wages/employee Rs ThNMNM1,010.31,143.01,139.4 
Avg. net profit/employee Rs ThNMNM574.2449.3600.0 
CIPLA INCOME DATA
Net Sales Rs m101,734113,454137,901146,302152,193 
Other income Rs m2,6541,6562,0822,2873,577 
Total revenues Rs m104,388115,110139,983148,589155,769 
Gross profit Rs m21,33121,61724,79724,75828,264 
Depreciation Rs m3,7265,0477,54213,22913,228 
Interest Rs m1,4571,6832,0661,5941,142 
Profit before tax Rs m18,80016,54317,27012,22217,470 
Minority Interest Rs m-159-482000 
Prior Period Items Rs m-123-253-120-70-28 
Extraordinary Inc (Exp) Rs m0000-775 
Tax Rs m4,6344,0003,3161,7982,501 
Profit after tax Rs m13,88411,80813,83410,35414,166 
Gross profit margin %21.019.118.016.918.6 
Effective tax rate %24.624.219.214.714.3 
Net profit margin %13.610.410.07.19.3 
CIPLA BALANCE SHEET DATA
Current assets Rs m56,51475,58288,41287,356108,141 
Current liabilities Rs m25,63637,61877,76133,73738,322 
Net working cap to sales %30.433.57.736.645.9 
Current ratio x2.22.01.12.62.8 
Inventory Days Days1041221018797 
Debtors Days Days5962626474 
Net fixed assets Rs m44,45248,521110,786111,567109,411 
Share capital Rs m1,6061,6061,6071,6091,610 
"Free" reserves Rs m98,591104,847113,555123,828140,682 
Net worth Rs m100,504106,453115,162125,437142,292 
Long term debt Rs m3,1793,0932,21936,45436,621 
Total assets Rs m134,032156,471211,282210,371228,606 
Interest coverage x13.910.89.48.716.3 
Debt to equity ratio x0000.30.3 
Sales to assets ratio x0.80.70.70.70.7 
Return on assets %11.48.67.55.76.7 
Return on equity %13.811.112.08.310.0 
Return on capital %19.316.016.48.510.0 
Exports to sales %48.641.748.534.232.8 
Imports to sales %14.014.712.58.30 
Exports (fob) Rs m49,48047,36366,83750,05049,883 
Imports (cif) Rs m14,26116,62917,27012,2030 
Fx inflow Rs m51,49949,10467,46151,06651,691 
Fx outflow Rs m18,94322,48324,72917,67821,033 
Net fx Rs m32,55626,62142,73333,38830,658 
CIPLA CASH FLOW
From Operations Rs m 15,633 11,734 17,408 23,818 14,628 
From Investments Rs m -12,499 -9,412 -45,226 -13,102 -8,540 
From Financial Activity Rs m -2,656 1,648 31,041 -13,257 -3,855 
Net Cashflow Rs m 478 3,971 3,123 -2,478 2,431 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 16.0%
Foreign collaborators 20.8%
Indian inst/Mut Fund 12.2%
FIIs 23.7%
ADR/GDR 1.1%
Free float 26.2%
Shareholders 161,166
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-13
E-MAIL cosecretary@cipla.com WEB www.cipla.com
TELEPHONE (022) 2482 6000 FAX (022) 2482 6893
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR V. Sankar Aiyar & Co.
CHM: Y. K. Hamied (MD) COMP SEC: Mital Sanghvi YEAR OF INC: 1935 BSE CODE: 500087 FV (Rs): 2 DIV YIELD (%): 0.5

More Pharmaceuticals Company Fact Sheets:   FDC LTD.  DISHMAN PHARMA  AJANTA PHARMA  INDRAPRASTHA MEDICAL  DIVIS LABORATORIES  

Compare CIPLA With:   FDC LTD.  DISHMAN PHARMA  AJANTA PHARMA  INDRAPRASTHA MEDICAL  DIVIS LABORATORIES  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 383 Points Lower; Realty and Auto Stocks Drag(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Views on news

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY18); Net Profit Down 347.8% (Quarterly Result Update)

May 24, 2018 | Updated on May 24, 2018

For the quarter ended March 2018, CIPLA has posted a net profit of Rs 2 bn (down 347.8% YoY). Sales on the other hand came in at Rs 37 bn (up 3.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

This Market Crash could be the Biggest Wealth Creating Opportunity Since 2008(Profit Hunter)

Oct 8, 2018

While widespread fear is the friend of a value investor, serving up bargain purchases; personal fear is an investor's biggest enemy.

IPO Market Feels the Heat of the Market Crash(Sector Info)

Oct 12, 2018

The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.

Are These Deep Corrections a Buying Signal?(Chart Of The Day)

Oct 5, 2018

The correction has bought many good companies to reasonable valuations. Go against the wisdom of crowd and Buy.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK CIPLA

MORE ON CIPLA

CIPLA - DISHMAN PHARMA COMPARISON

COMPARE CIPLA WITH

MARKET STATS